JP2005534661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534661A5 JP2005534661A5 JP2004511295A JP2004511295A JP2005534661A5 JP 2005534661 A5 JP2005534661 A5 JP 2005534661A5 JP 2004511295 A JP2004511295 A JP 2004511295A JP 2004511295 A JP2004511295 A JP 2004511295A JP 2005534661 A5 JP2005534661 A5 JP 2005534661A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- injury
- peripheral
- alopecia
- metastases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 201000004384 alopecia Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000926 neurological Effects 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (1)
- 中枢または末梢性神経変性病；筋萎縮性側索硬化症、多発性硬化症；心臓血管病；末梢神経疾患；視神経および網膜損傷；脊髄損傷および頭蓋損傷；アテローム性動脈硬化症；狭窄；瘢痕形成；脱毛症；癌；腫瘍；転移；白血病；慢性神経性および炎症性疼痛；自己免疫疾患；骨折；骨疾患の予防または治療のための、請求項１〜６のいずれか一つに記載の式(I)の化合物を含む医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207001 | 2002-06-07 | ||
| PCT/FR2003/001685 WO2003104225A1 (fr) | 2002-06-07 | 2003-06-05 | Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005534661A JP2005534661A (ja) | 2005-11-17 |
| JP2005534661A5 true JP2005534661A5 (ja) | 2006-05-11 |
| JP4437075B2 JP4437075B2 (ja) | 2010-03-24 |
Family
ID=29724874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004511296A Expired - Fee Related JP4441401B2 (ja) | 2002-06-07 | 2003-06-05 | ピペラジニルアシルピペリジン誘導体、それらの製造およびそれらの治療的用途 |
| JP2004511295A Expired - Fee Related JP4437075B2 (ja) | 2002-06-07 | 2003-06-05 | ピペラジニルアシルピペリジン誘導体、それらの製造方法およびそれらの治療的用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004511296A Expired - Fee Related JP4441401B2 (ja) | 2002-06-07 | 2003-06-05 | ピペラジニルアシルピペリジン誘導体、それらの製造およびそれらの治療的用途 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7468368B2 (ja) |
| EP (2) | EP1513836B1 (ja) |
| JP (2) | JP4441401B2 (ja) |
| KR (1) | KR100970812B1 (ja) |
| CN (1) | CN100448875C (ja) |
| AR (2) | AR040246A1 (ja) |
| AT (2) | ATE336491T1 (ja) |
| AU (2) | AU2003255645A1 (ja) |
| BR (1) | BR0311828A (ja) |
| CA (1) | CA2487840C (ja) |
| CY (2) | CY1107330T1 (ja) |
| DE (2) | DE60305037T2 (ja) |
| DK (2) | DK1513835T3 (ja) |
| EA (1) | EA007501B1 (ja) |
| ES (2) | ES2271637T3 (ja) |
| HK (1) | HK1076110A1 (ja) |
| HR (1) | HRP20041157B1 (ja) |
| IS (1) | IS2302B (ja) |
| MA (1) | MA27233A1 (ja) |
| ME (1) | MEP11508A (ja) |
| MX (1) | MXPA04012341A (ja) |
| NO (1) | NO329669B1 (ja) |
| NZ (1) | NZ537044A (ja) |
| PL (1) | PL208711B1 (ja) |
| PT (2) | PT1513835E (ja) |
| RS (2) | RS52588B (ja) |
| TW (2) | TWI283671B (ja) |
| UA (1) | UA77526C2 (ja) |
| WO (2) | WO2003104226A1 (ja) |
| ZA (1) | ZA200409823B (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| WO2005068445A2 (en) * | 2004-01-08 | 2005-07-28 | Syngenta Participations Ag | Pesticidal heterocyclic dihaloallyl compounds |
| AU2005263718A1 (en) * | 2004-07-16 | 2006-01-26 | Janssen Pharmaceutica N.V. | Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders |
| CN101083982A (zh) * | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物 |
| JP2008536844A (ja) | 2005-04-15 | 2008-09-11 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ニューロトロフィン類似体を用いた細胞生存促進法 |
| CA2680583A1 (en) * | 2007-03-15 | 2008-09-25 | Schering Corporation | Pyridazinone derivatives useful as glucan synthase inhibitors |
| MX2009012506A (es) * | 2007-05-21 | 2009-12-09 | Reviva Pharmaceuticals Inc | Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona. |
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| FR2932481B1 (fr) * | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique. |
| FR2932482B1 (fr) * | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| JP5863663B2 (ja) | 2009-11-12 | 2016-02-16 | ファーマトロフィックス， インコーポレイテッド | ニューロトロフィン模倣化合物およびこれらの塩の結晶形態 |
| FR2953839A1 (fr) * | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| EP2513057B1 (de) | 2009-12-14 | 2013-09-04 | Merck Patent GmbH | Inhibitoren der sphingosinkinase |
| FR2953836B1 (fr) | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| WO2019055966A2 (en) * | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | PYRIDAZINONES AND METHODS OF USE |
| PT3852533T (pt) | 2018-09-18 | 2024-05-31 | Gfb Abc Llc | Piridazinonas e métodos de utilização das mesmas |
| EP3858439A1 (en) * | 2020-02-03 | 2021-08-04 | Esteve Pharmaceuticals, S.A. | Amide derivatives having multimodal activity against pain |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173180B (es) * | 1987-10-26 | 1994-02-07 | Pfizer | Procedimiento para preparar agentes ansioliticos |
| FR2747041B1 (fr) * | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| FR2803593B1 (fr) | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
-
2003
- 2003-05-06 UA UA20041210010A patent/UA77526C2/uk unknown
- 2003-06-05 RS RS20050014A patent/RS52588B/en unknown
- 2003-06-05 JP JP2004511296A patent/JP4441401B2/ja not_active Expired - Fee Related
- 2003-06-05 AT AT03757108T patent/ATE336491T1/de active
- 2003-06-05 CN CNB038188082A patent/CN100448875C/zh not_active Expired - Fee Related
- 2003-06-05 PT PT03757108T patent/PT1513835E/pt unknown
- 2003-06-05 AU AU2003255645A patent/AU2003255645A1/en not_active Abandoned
- 2003-06-05 CA CA2487840A patent/CA2487840C/en not_active Expired - Fee Related
- 2003-06-05 JP JP2004511295A patent/JP4437075B2/ja not_active Expired - Fee Related
- 2003-06-05 US US10/516,704 patent/US7468368B2/en active Active
- 2003-06-05 PL PL374729A patent/PL208711B1/pl not_active IP Right Cessation
- 2003-06-05 RS YUP-2005/0014A patent/RS20050014A/sr unknown
- 2003-06-05 EA EA200401470A patent/EA007501B1/ru not_active IP Right Cessation
- 2003-06-05 DE DE60305037T patent/DE60305037T2/de not_active Expired - Lifetime
- 2003-06-05 NZ NZ537044A patent/NZ537044A/en not_active IP Right Cessation
- 2003-06-05 DE DE60307632T patent/DE60307632T2/de not_active Expired - Lifetime
- 2003-06-05 ES ES03757108T patent/ES2271637T3/es not_active Expired - Lifetime
- 2003-06-05 EP EP03757109A patent/EP1513836B1/fr not_active Expired - Lifetime
- 2003-06-05 WO PCT/FR2003/001686 patent/WO2003104226A1/fr active IP Right Grant
- 2003-06-05 AT AT03757109T patent/ATE325122T1/de active
- 2003-06-05 EP EP03757108A patent/EP1513835B1/fr not_active Expired - Lifetime
- 2003-06-05 DK DK03757108T patent/DK1513835T3/da active
- 2003-06-05 US US10/516,808 patent/US7294628B2/en active Active
- 2003-06-05 AU AU2003255644A patent/AU2003255644B2/en not_active Ceased
- 2003-06-05 ES ES03757109T patent/ES2264001T3/es not_active Expired - Lifetime
- 2003-06-05 DK DK03757109T patent/DK1513836T3/da active
- 2003-06-05 BR BR0311828-2A patent/BR0311828A/pt not_active IP Right Cessation
- 2003-06-05 KR KR1020047019860A patent/KR100970812B1/ko not_active IP Right Cessation
- 2003-06-05 PT PT03757109T patent/PT1513836E/pt unknown
- 2003-06-05 MX MXPA04012341A patent/MXPA04012341A/es active IP Right Grant
- 2003-06-05 WO PCT/FR2003/001685 patent/WO2003104225A1/fr active IP Right Grant
- 2003-06-05 ME MEP-115/08A patent/MEP11508A/xx unknown
- 2003-06-06 AR ARP030102017A patent/AR040246A1/es active IP Right Grant
- 2003-06-06 AR ARP030102018A patent/AR040247A1/es active IP Right Grant
- 2003-06-06 TW TW092115416A patent/TWI283671B/zh not_active IP Right Cessation
- 2003-06-06 TW TW092115443A patent/TWI319400B/zh not_active IP Right Cessation
-
2004
- 2004-12-02 IS IS7579A patent/IS2302B/is unknown
- 2004-12-03 MA MA27980A patent/MA27233A1/fr unknown
- 2004-12-03 ZA ZA200409823A patent/ZA200409823B/en unknown
- 2004-12-06 NO NO20045331A patent/NO329669B1/no not_active IP Right Cessation
- 2004-12-06 HR HR20041157 patent/HRP20041157B1/xx not_active IP Right Cessation
-
2005
- 2005-11-19 HK HK05110460.5A patent/HK1076110A1/xx not_active IP Right Cessation
-
2006
- 2006-08-03 CY CY20061101094T patent/CY1107330T1/el unknown
- 2006-11-15 CY CY20061101660T patent/CY1105784T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005534661A5 (ja) | ||
| JP2005533051A5 (ja) | ||
| CY2013022I1 (el) | Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων | |
| HUS1400011I1 (hu) | Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére | |
| IL180979A (en) | Isoindulin compounds and their use | |
| SI2527315T1 (sl) | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen | |
| NO20043237L (no) | Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser | |
| MXPA05009595A (es) | Compuestos 7-amino-isoindolilo y sus usos farmaceuticos. | |
| AU2002252373A1 (en) | Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders | |
| HK1092367A1 (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| WO2008002621A3 (en) | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | |
| NO20053678D0 (no) | Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser | |
| EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
| EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
| NO20054640D0 (no) | Fremgangsmater for behandling av Parkinsons sykdom | |
| EP1818325A3 (en) | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | |
| TW200745135A (en) | Therapeutic agents | |
| HK1086011A1 (en) | Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease | |
| WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
| ZA200505996B (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
| HUP0304095A2 (hu) | Új, nagyhatású gyógyszerkészítmények | |
| AU2003274885A1 (en) | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | |
| WO2005020904A3 (en) | Oral neurotherapeutic cefazolin compositions | |
| EP1546120A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| HRP20040104A2 (en) | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |